Traditionally, as a former division of a large multinational pharmaceutical company, the R&D unit had several areas of interest, with three main areas of expertise for the discovery and development of drug candidates: rheumatology, gastroenterology, and gynaecology. And thanks to the commitment of the R&D unit, different successful products were developed in these therapeutic areas.
As an independent company, Rottapharm Biotech has elected to initially focus on rheumatic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA), a field where its scientists are internationally recognized scientific authorities. A multilevel approach has been implemented to discover and develop innovative symptom-modifying and disease-modifying drugs. To date, five projects at different stages of active development are comprised in a coherent yet varied core pipeline: the Rottapharm Biotech’s Rheumatology Platform.